Glembatumumab is a human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be linked to monomethyl auristatin E (MMAE) to form Glembatumumab vedotin, an ADC for cancer therapy.